Recent

% | $
Quotes you view appear here for quick access.

Celgene Corporation Message Board

  • zilablue zilablue Nov 29, 2012 12:05 AM Flag

    Canaccord Genuity Reiterates Buy on Avanir (AVNR) as Drug Sales Ramp

    Canaccord Genuity Reiterates Buy on Avanir (AVNR) as Drug Sales Ramp

    November 28, 2012 2:23 PM EST
    Canaccord Genuity maintained a Buy on Avanir Pharmaceuticals (NASDAQ: AVNR) with a price target of $6.00 after the company reported drug sales that beat estimates. Nuedexta gross sales came in a $15.4 million, beating consensus views of $14.8 million.

    Commenting on the developments, analysts Ritu Baral said, "Recent sales trends continue to appear steady, and we foresee continued sales ramp in 2013."

    Canaccord Genuity's $6 target on Avanir Pharmaceuticals (NASDAQ: AVNR) is based on a sum-of- the-parts analysis

    Sentiment: Strong Buy

 
CELG
100.25-1.46(-1.44%)May 6 4:00 PMEDT